Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer

X
Trial Profile

Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niraparib (Primary) ; Oregovomab (Primary)
  • Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FLORA-4
  • Sponsors OncoQuest
  • Most Recent Events

    • 04 Jun 2024 Results(Between July 2022 and June 2023, N=10) assessing the safety and activity of combination oregovomab and niraparib in platinum sensitive EOC , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 11 Jan 2024 Planned End Date changed from 30 Oct 2024 to 30 Dec 2024.
    • 11 Jan 2024 Planned primary completion date changed from 30 Jan 2024 to 30 Mar 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top